Prevenar 13 filed for approval in Japan but reimbursement uncertain at present
This article was originally published in Scrip
Executive Summary
Pfizer has filed for the approval of its enhanced paediatric use pneumococcal conjugate vaccine Prevenar 13 in Japan, although it is not clear yet whether the administration of the product will be granted government financial support.